Cell-extracellular matrix interactions have important roles in many biological processes, including embryonic development, growth control and differentiation. Integrins are the principal receptors for extracellular matrix. They are composed of non-covalently associated alpha and beta chains. Integrin alpha 6 can associate with either beta 1 or beta 4 (refs 2,3). Both integrin complexes are receptors for laminins, major components of basement membranes. The distribution of alpha 6 (refs 4-10) as well as studies using function-blocking antibodies have suggested an essential role for this laminin receptor during embryogenesis, in processes such as endoderm migration or kidney tubule formation9. Here we report that, surprisingly, mice lacking the alpha 6 integrin chain develop to birth. However, they die at birth with severe blistering of the skin and other epithelia, a phenotype reminiscent of the human disorder epidermolysis bullosa. Hemidesmosomes are absent in mutant tissue. This absence is likely to result from the lack of alpha 6/beta 4, the only integrin in hemidesmosomes of stratified squamous and transitional epithelia. Mutations in the genes encoding integrin beta 4 and chains of laminin-5 have been implicated in junctional epidermolysis bullosa. Our study provides evidence that some forms of epidermolysis bullosa may originate from defects of the alpha 6 gene.

In this study we generated a novel dual specific phosphatase 4 (DUSP4) deletion mouse using a targeted deletion strategy in order to examine the role of MAP kinase phosphatase-2 (MKP-2) in immune responses. Lipopolysaccharide (LPS) induced a rapid, time and concentration-dependent increase in MKP-2 protein expression in bone marrow-derived macrophages from MKP-2+/+ but not from MKP-2−/− mice. LPS-induced JNK and p38 MAP kinase phosphorylation was significantly increased and prolonged in MKP-2−/− macrophages whilst ERK phosphorylation was unaffected. MKP-2 deletion also potentiated LPS-stimulated induction of the inflammatory cytokines, IL-6, IL-12p40, TNF-α, and also COX-2 derived PGE2 production. However surprisingly, in MKP-2−/− macrophages, there was a marked reduction in LPS or IFNγ-induced iNOS and nitric oxide release and enhanced basal expression of arginase-1, suggesting that MKP-2 may have an additional regulatory function significant in pathogen-mediated immunity. Indeed, following infection with the intracellular parasite Leishmania mexicana, MKP-2−/− mice displayed increased lesion size and parasite burden, and a significantly modified Th1/Th2 bias compared with wild-type counterparts. However, there was no intrinsic defect in MKP-2−/− T cell function as measured by anti-CD3 induced IFN-γ production. Rather, MKP-2−/− bone marrow-derived macrophages were found to be inherently more susceptible to infection with Leishmania mexicana, an effect reversed following treatment with the arginase inhibitor nor-NOHA. These findings show for the first time a role for MKP-2 in vivo and demonstrate that MKP-2 may be essential in orchestrating protection against intracellular infection at the level of the macrophage.

No abstract

Mitogen-activated protein kinase phosphatase-2 (MKP-2The amplitude and duration of MAP kinase signaling within a specific subcellular compartment are key features in the integration of extracellular stimuli and their effects on cellular (1). Three main MAP kinase groups, the ERKs, JNK, and p38 MAP kinases, are involved in regulating functions such as proliferation, apoptosis, and differentiation in response to growth factors, peptide hormones, stress, and infection (2). Perturbations in MAP kinase signaling are features of several different types of diseases including several types of cancers (3), diabetes (4), atherosclerosis (5, 6), and immune disorders.The kinetics of MAP kinase activation are strictly controlled principally by the mitogen-activated protein kinase phosphatases (MKPs), 3 a family of at least 10 dual specific phosphatases (DUSPs) that function to terminate MAP kinase signaling within a defined subcellular location (7). They share a common C-terminal catalytic domain and an N-terminal non-catalytic domain containing the MAP kinase interaction motif (8). Each isoform has unique yet overlapping features including substrate specificity, subcellular distribution, and factors regulating induction. For example, MKP-1 is a nuclear DUSP of the type 1 class and selective for all three major MAP kinases in vitro, whereas MKP-3, a type II DUSP, is a cytosolic phosphatase selective solely for ERK over the other kinases (7). Due to effects upon MAP kinase signaling, pertubations in the MKPs have been implicated principally in cancer (9). However, more recently, a role has been established in inflammation (10) and some cardiovascular disorders (11).One poorly studied MKP is MKP-2 (12). This DUSP (DUSP-4) is a member of the type 1 family and has been shown to be induced in response to a number of stimuli including phorbol esters and growth hormones (12-14). Nuclear targeting is regulated by two distinct nuclear targeting sequences (15). Substrate specificity for ERK and JNK was originally demonstrated in vitro (16); however, selective inhibition of JNK has been implicated in cellular studies (17,18). Although MKP-2 has been recently regarded as a surrogate for the more well described MKP-1, recent cellular studies demonstrate a role in protection against apoptosis (17) and in senescence (19). However, there is still a lack of information describing the function of DUSP-4 in different cell types, in particular regarding substrate selectivity in vivo.We have recently developed a DUSP-4 deletion mouse model and demonstrated a novel immunological phenotype in vivo (20). Using embryonic fibroblasts from DUSP-4 deletion mice, we now examine the effect of deletion upon MAP kinase signaling and growth parameters. We find that despite very moderate increases in ERK and JNK activity, MKP-2 deletion has profound effects upon cellular proliferation. In particular, we identify a role for MKP-2 in G 2 /M phase transition and demonstrate that MKP-2 plays a role in cell survival in response to the apo-* This work was supporte...

No abstract

We assessed the effects of over-expressing the dual-specific phosphatase, mitogen-activated protein (MAP) kinase phosphatase-2 (MKP-2), in human umbilical vein endothelial cells (HUVECs) on inflammatory protein expression and apoptosis, two key features of endothelial dysfunction in disease. EXPERIMENTAL APPROACHESWe infected HUVECs for 40 h with an adenoviral version of MKP-2 (Adv.MKP-2). Tumour necrosis factor (TNF)-a-stimulated phosphorylation of MAP kinase and protein expression was measured by Western blotting. Cellular apoptosis was assayed by FACS. KEY RESULTSInfection with Adv.MKP-2 selectively abolished TNF-a-mediated c-Jun-N-terminal kinase (JNK) activation and had little effect upon extracellular signal-regulated kinase or p38 MAP kinase. Adv.MKP-2 abolished COX-2 expression, while induction of the endothelial cell adhesion molecules, intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM), two NFkB-dependent proteins, was not affected. However, when ICAM and VCAM expression was partly reduced by blockade of the NFkB pathway, Adv.MKP-2 was able to reverse this inhibition. This correlated with enhanced TNF-a-induced loss of the inhibitor of kB (IkB)a loss, a marker of NFkB activation. TNF-a in combination with NFkB blockade also increased HUVEC apoptosis; this was significantly reversed by Adv.MKP-2. Protein markers of cellular damage and apoptosis, H2AX phosphorylation and caspase-3 cleavage, were also reversed by MKP-2 over-expression. CONCLUSIONS AND IMPLICATIONSOver-expression of MKP-2 had different effects upon the expression of inflammatory proteins due to a reciprocal effect upon JNK and NFkB signalling, and also prevented TNF-a-mediated endothelial cell death. These properties may make Adv.MKP-2 a potentially useful future therapy in cardiovascular diseases where endothelial dysfunction is a feature. AbbreviationsAdv., adenovirus; HUVECs, human umbilical vein endothelial cells; ICAM, intercellular adhesion molecule; IKK, inhibitory kappa B kinase; JNK, c-Jun-N-terminal kinase; MKP-2, MAP kinase phosphatase-2; TNF-a, tumour necrosis factor-a; VCAM, vascular cell adhesion molecule BJP British Journal of Pharmacology

No abstract

No abstract